Business Wire

Senegal Inaugurates its Regional Express Train Linking Dakar to Diamniadio

Share

On Monday 27 December 2021, the Republic of Senegal, represented by its President, H.E. Macky Sall, officially launched the commercial operation of the Regional Express Train (RET) which will link Dakar, the country's capital, to Diamniadio, the new town currently under development. The rail link will extend over 35 kilometers with the aim of serving nearly 115,000 travelers daily using its 14 trains, each with a capacity of 565 passengers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211228005128/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

As a flagship project of the Plan for an Emerging Senegal, which aims to deliver an "emerging Senegal in 2035", the RET is equipped with state-of-the-art "dual-mode" technology. It relies on electrical energy as well as thermal energy, allowing the trains to travel at a top speed of 160 km/h. In addition, all of these trains are equipped with air conditioning, on-board WiFi access and reading lights.

The completion of this project, which connects the center of Dakar to the new Blaise Diagne International Airport (about 50 km from the capital), should ease congestion in the region by transporting 115,000 passengers per day and providing 196 train journeys per day. The project embodies the forward-looking, long-term vision of the President of the Republic, H.E. Macky Sall. This strategy has led to several projects fostering development and innovation, particularly in terms of transport infrastructure, with the provision of the Highway of the Future.

"The Regional Express Train is not only a rapid means of transport. In fact, it is more than just a journey from one train station to another, it is a high-speed journey propelling us into the modern age. We are proud of this launch which provides proof of Senegal's progress in terms of inter-connectivity, and we thank our partners for their support," declared the President of the Republic, H.E. Macky Sall, at the inauguration of the first train journey. He also emphasized the impact of the project on the growth and development of the country.

The construction of this initial rail link of the Regional Express Train (RET) was entrusted to the Agence pour la Promotion des Investissements et Grands Travaux du Sénégal (Apix SA). The works have been split into two phases, the first phase will link Dakar to Diamniadio (36 km) and the second phase will link Diamniadio to the Blaise Diagne International Airport (an additional 19 km). The line will serve 14 stations, including Dakar, Diamniadio and Rufisque.

The Dakar-Diamniadio Regional Express Train is one of several priorities of the Senegalese authorities in terms of infrastructure projects. Others include the Bus Rapid Transit (BRT) project, a structuring project for the Dakar metropolitan area and promoting mobility in this region.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press:
35°Nord – Press relations and strategic communications agency
Goudet Abalé (Senior consultant)
E-mail:ga@35nord.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye